Christine Jihae Park

Christine Jihae Park serves as a Contracting Specialist responsible for managing complex acquisitions in the biotechnology and biological manufacturing sectors. She plays a pivotal role in ensuring that agency procurement activities align with federal regulatory standards and scientific mission objectives, overseeing the full lifecycle of contracts from solicitation through award and administration. Her acquisitions typically involve research and development services, clinical process validation, and manufacturing of biological products, requiring deep technical understanding and compliance with FDA-aligned quality systems. She works closely with scientific stakeholders to translate technical requirements into enforceable contract language and performance metrics. Christine engages with a diverse array of contractors, primarily including specialized biotech firms and GMP-certified manufacturing vendors with expertise in cell and gene therapy, recombinant protein production, and process scale-up. While no single contractor dominates her portfolio, she consistently collaborates with firms possessing validated cGMP facilities, analytical method development capabilities, and experience in regulatory submissions. Her contracting approach emphasizes performance-based outcomes, risk mitigation, and rigorous contractor oversight to ensure product integrity and compliance. Christine’s procurement patterns reflect a strong preference for open competition, with 100% of her awards designated as “No Set-Aside.” She does not routinely utilize socioeconomic set-asides such as 8(a), HUBZone, or SDVOSB programs, instead prioritizing technical capability and regulatory readiness as the primary selection criteria. This approach underscores a mission-driven focus on scientific rigor over socioeconomic preferences, though she remains compliant with all applicable small business goals and reporting requirements. Her primary procurement focus lies in NAICS 541714 (Research and Development in Biotechnology), where she manages contracts for novel therapeutic development, biomarker discovery, and preclinical validation studies. She also frequently procures services under NAICS 325414 (Biological Product Manufacturing), ensuring contractors meet stringent sterility, purity, and traceability standards. Her domain expertise centers on advanced biologics, including monoclonal antibodies, viral vectors, and cell-based therapeutics, making her a key liaison between scientific innovation and federal acquisition policy.